drug · small molecule
surufatinib
Phase 2updated 3mo agoby $HCM HUTCHMED (China) Ltd🔗 ChEMBL
Phase 2community read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and 26 investigational indications.
targets
Fibroblast growth factor receptor 1Vascular endothelial growth factor receptor
all catalysts(0)
nothing on the calendar yet
Trials studying surufatinib
- phase2Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer
- phase3A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
- phase2Open-label Study of Surufatinib in Japanese Patients
- phase2Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
- phase2Open-Label Surufatinib in European Patients With NET
- phase2Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
- phase2HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma
- phase2A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 18m ago
Found something off?
comments(0)
5-min edit window · permanent after that